We are often asked to research, compile and deliver comprehensive reports detailing particular aspects of the UK regulatory, pricing and reimbursement, or access landscape to support the ongoing clinical development or launch of a new pharmaceutical product or medical device.

In recent months, we’ve delivered reports on CAR-T cell therapies and Parkinson’s disease. In the first example, the final report included an overview of the pricing and reimbursement landscape in England, Scotland, Wales and Northern Ireland, a comprehensive technical analysis and commentary of completed CAR-T  health technology appraisals (HTAs) by the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC), summaries of relevant policy documents and hyperlinks to webpages, plus an assessment of key HTA challenges and issues for emerging gene therapies.

The second report had a somewhat different focus – the client was primarily interested in the clinical management and prescribing environment in the UK. In addition to a written report, we produced a slide deck presenting a health economic and outcomes research (HEOR) gap analysis and recommendations for HEOR evidence generation to support a future HTA.